Compare IQIYI Inc - ADR (IQ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs State Street SPDR S&P Biotech ETF — how do they compare? IQIYI Inc - ADR trades at $1.02 (market cap $974.67M), while State Street SPDR S&P Biotech ETF trades at $153.99 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 10.4× IQIYI Inc - ADR's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| IQ | XBI | |
|---|---|---|
Market Cap | $974.67M | $10.11B |
Volume | 4,964,108 | 12,903,266 |
Sector | Media | Broad Market / Factor |
52-Week High | $2.35 | $169.55 |
52-Week Low | $0.86 | $104.99 |
Typical Hold Time | 55 Days | 38 Days |
Enterprise Value | $2.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ trades at $1.025, up 0.99% today, but technicals are bearish with mixed sentiment. The company reported a net loss of $206.31M in 2025 despite beating EPS estimates in recent quarters. Revenue declined to $27.29B, and profitability metrics like ROE are negative. Analyst consensus is split with 50% buy ratings, but cash flow trends show volatility, and the firm is heavily investing in AI-driven content.
Outlook is cautious; while AI initiatives offer growth potential, core streaming pressures and persistent losses pose risks. The stock's low P/S and P/B suggest undervaluation, but investor confidence hinges on a return to profitability and successful execution of new content strategies amid competitive and macroeconomic challenges.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
